# TB-500

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/tb-500-product
Canonical HTML page: https://gethealthbrief.com/entity/tb-500-product

## Timeline

- **2026-07-24**: PCAC Votes to Recommend Six Peptides — The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
- **2026-07-23**: FDA PCAC Public Meeting Begins — The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.

## Recent coverage (2 stories)

### 6 Anti-Aging Peptides Move Closer to FDA Compounding Approval, Vanta Builds Health Platform
2026-08-01 14:28:46 · Sentiment: Very Bullish · Impact: 6/10 · Sources: 2

A key FDA panel vote could expand legal access to BPC-157, TB-500, and four other peptides through compounding pharmacies. Vanta is positioning its telehealth and pharmacy network to deliver these therapies to consumers seeking longevity care.
Full story: https://gethealthbrief.com/story/fda-committee-six-peptides-health-it

### FDA Panel Votes 8-6 to Lift Peptide Curbs, Fueling Telehealth Safety Fears
2026-08-01 12:31:51 · Sentiment: Bullish · Impact: 6/10 · Sources: 3

An FDA advisory committee voted 8-6 to recommend allowing pharmacy compounding of unapproved peptides like BPC-157, raising urgent questions about patient safety, telehealth marketing practices, and regulatory integrity.
Full story: https://gethealthbrief.com/story/fda-panel-8-6-vote-peptide-telehealth-safety

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.